Patent filing numbers raise more concerns over antibiotic innovation
This article was originally published in Scrip
New figures detailing the number of patent filings in the antibiotic space suggests that the issue of resistance is still not being addressed adequately. The fact that the antibiotic industry is not innovating at the same pace as other areas of the pharmaceutical industry has been highlighted through an analysis of filings over the past ten years by IP lawyers at Marks & Clerk. In its latest report, From rare to routine – medicines for rare diseases, vaccines and antibiotics, the firm emphasizes why it believes that the antibiotics market is "at risk of losing another decade to inadequate levels of research and innovation."